首页 > 最新文献

Therapeutics and Clinical Risk Management最新文献

英文 中文
Bone Remodelling of the Proximal Femur After Hip Revision with a Metaphyseal-Fixation Femoral Stem Component. 股骨干骺端固定假体髋关节翻修后股骨近端骨重建。
IF 2.8 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S393876
Zhijie Li, Mengnan Li, Xiaowei Yao, Bo Liu, Sikai Liu, Zeming Liu, Binquan Zhang, Yongtai Han

Background: Whether hip revision with a metaphyseal-fixation femoral stem component can restore the bone mass of the proximal femur remains unclear. The aims of this study were to identify whether the bone mineral density (BMD) of the proximal femur increases following hip revision with a metaphyseal-fixation femoral stem and to identify the factors associated with BMD recovery.

Methods: This was a retrospective study involving 36 patients who underwent hip arthroplasty with a metaphyseal-diaphyseal fixation stem (standard length stem) and had indications for hip revision, which was performed with a proximal press-fit short-stem prosthesis for each patient. Dual-energy X-ray absorptiometry (DEXA) was used to obtain, evaluate, and compare the BMD at baseline and one year and two years postoperatively. The proximal femur was divided into several independent areas according to the Gruen zone (Gruen 1 to Gruen 7 from the greater trochanter counterclockwise to the lesser trochanter). Logistic regression analyses were used to assess potential factors significantly associated with an increase in BMD.

Results: An increased BMD was obviously identified in the proximal femur. Two years after the surgery, the BMD of the Gruen 1, Gruen 2, Gruen 6, and Gruen 7 areas had increased by 22.6%, 12.6%, 16.2% and 24.2%, respectively, relative to baseline. Three independent risk factors associated with bone mineral density recovery were identified: age (OR=1.100, 95% CI=1.005-1.203, P=0.038), osteoporosis (OR=14.921, 95% CI=1.223-182.101, P=0.034) and fair to poor hip function (OR=13.142, 95% CI=1.024-168.582, P=0.048).

Conclusion: This study confirms that metaphyseal-fixation stem hip revision can indeed help restore bone mass in the proximal femur, especially in the Gruen 1, Gruen 2, Gruen 6 and Gruen 7 zones. It was also found that advanced age, osteoporosis, and fair to poor hip joint function were three important risk factors affecting the recovery of proximal femur bone mass after surgery.

Trial registration: Retrospectively registered.

背景:采用干骺端固定股骨干假体进行髋关节翻修是否能恢复股骨近端骨量尚不清楚。本研究的目的是确定股骨近端骨矿物质密度(BMD)是否在股骨干骺端固定髋关节翻修后增加,并确定与BMD恢复相关的因素。方法:这是一项回顾性研究,涉及36例采用干骺端-干骺端固定柄(标准长度柄)进行髋关节置换术并有髋关节翻修指征的患者,每位患者使用近端加压短柄假体进行髋关节翻修。采用双能x线骨密度仪(DEXA)获取、评估和比较基线、术后1年和2年的骨密度。根据Gruen区(Gruen 1 ~ Gruen 7,从大转子逆时针方向至小转子)将股骨近端分成几个独立区域。Logistic回归分析用于评估与骨密度增加显著相关的潜在因素。结果:股骨近端骨密度明显增高。术后2年,gruen1、gruen2、gruen6和gruen7区的骨密度分别较基线增加22.6%、12.6%、16.2%和24.2%。确定了与骨密度恢复相关的三个独立危险因素:年龄(OR=1.100, 95% CI=1.005-1.203, P=0.038)、骨质疏松(OR=14.921, 95% CI=1.223-182.101, P=0.034)和髋关节功能差(OR=13.142, 95% CI=1.024-168.582, P=0.048)。结论:本研究证实,干骺端固定髋关节翻修确实有助于股骨近端骨量的恢复,特别是在gruen1、gruen2、gruen6和gruen7区。高龄、骨质疏松、髋关节功能一般到较差是影响术后股骨近端骨量恢复的三个重要危险因素。试验注册:回顾性注册。
{"title":"Bone Remodelling of the Proximal Femur After Hip Revision with a Metaphyseal-Fixation Femoral Stem Component.","authors":"Zhijie Li,&nbsp;Mengnan Li,&nbsp;Xiaowei Yao,&nbsp;Bo Liu,&nbsp;Sikai Liu,&nbsp;Zeming Liu,&nbsp;Binquan Zhang,&nbsp;Yongtai Han","doi":"10.2147/TCRM.S393876","DOIUrl":"https://doi.org/10.2147/TCRM.S393876","url":null,"abstract":"<p><strong>Background: </strong>Whether hip revision with a metaphyseal-fixation femoral stem component can restore the bone mass of the proximal femur remains unclear. The aims of this study were to identify whether the bone mineral density (BMD) of the proximal femur increases following hip revision with a metaphyseal-fixation femoral stem and to identify the factors associated with BMD recovery.</p><p><strong>Methods: </strong>This was a retrospective study involving 36 patients who underwent hip arthroplasty with a metaphyseal-diaphyseal fixation stem (standard length stem) and had indications for hip revision, which was performed with a proximal press-fit short-stem prosthesis for each patient. Dual-energy X-ray absorptiometry (DEXA) was used to obtain, evaluate, and compare the BMD at baseline and one year and two years postoperatively. The proximal femur was divided into several independent areas according to the Gruen zone (Gruen 1 to Gruen 7 from the greater trochanter counterclockwise to the lesser trochanter). Logistic regression analyses were used to assess potential factors significantly associated with an increase in BMD.</p><p><strong>Results: </strong>An increased BMD was obviously identified in the proximal femur. Two years after the surgery, the BMD of the Gruen 1, Gruen 2, Gruen 6, and Gruen 7 areas had increased by 22.6%, 12.6%, 16.2% and 24.2%, respectively, relative to baseline. Three independent risk factors associated with bone mineral density recovery were identified: age (OR=1.100, 95% CI=1.005-1.203, P=0.038), osteoporosis (OR=14.921, 95% CI=1.223-182.101, P=0.034) and fair to poor hip function (OR=13.142, 95% CI=1.024-168.582, P=0.048).</p><p><strong>Conclusion: </strong>This study confirms that metaphyseal-fixation stem hip revision can indeed help restore bone mass in the proximal femur, especially in the Gruen 1, Gruen 2, Gruen 6 and Gruen 7 zones. It was also found that advanced age, osteoporosis, and fair to poor hip joint function were three important risk factors affecting the recovery of proximal femur bone mass after surgery.</p><p><strong>Trial registration: </strong>Retrospectively registered.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"19 ","pages":"171-181"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a4/48/tcrm-19-171.PMC9938707.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10827249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasonographic Assessment of Gastric Volume in Fasted Patients Undergoing Gastrointestinal Endoscopy Under Sedation. 镇静下禁食胃肠内镜检查患者胃容量的超声评估。
IF 2.8 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S424890
Heng Rong, Weixin Dai, Yinying Qin, Zhikeng Meng, Xia Zou, Binbin Wang, Qiufeng Wei, Yubo Xie

Purpose: In this prospective observational study, an ultrasonographic measurement of antral cross-sectional area (ACSA) was conducted to evaluate the gastric content and volume as well as to identify high-risk stomach in non-pregnant adult surgical patients adhering to preanesthetic fasting guidelines.

Patients and methods: Fasted patients undergoing gastrointestinal endoscopy under sedation were included. Ultrasonographic measurements of ACSA were conducted in both semi-recumbent and right lateral decubitus positions before endoscopic procedures. Gastroscopy was employed to guide the measurement of suctioned gastric volume (GV). Ultrasonography was performed to assess gastric contents and identify patients with high-risk stomach. The relationship between ACSA and suctioned GV was also evaluated.

Results: ACSA was evaluated in 736 out of 782 patients. A significant positive correlation was discovered between ACSA in the right lateral decubitus position and suctioned GV, which was more reliable than in the semi-recumbent position. To analyze high-risk stomach with a GV > 100 mL, the cutoff value of ACSA in the right lateral decubitus was found to be 7.5 cm2, with the AUC, sensitivity and specificity of 0.80 (95% CI, 0.76-0.82; P<0.001), 82.4% and 67.3%, respectively. A novel mathematical model based on ACSA to estimate GV in non-pregnant fasted adults was presented.

Conclusion: Ultrasonographic measurement of ACSA can assist anesthesiologists in estimating the risk of pulmonary aspiration of gastric contents during general anesthesia and sedation.

目的:在这项前瞻性观察研究中,通过超声测量胃窦横断面积(ACSA)来评估非妊娠成人手术患者遵守麻醉前禁食指南的胃内容物和胃容量,并识别高危胃。患者和方法:纳入镇静下禁食的胃肠内镜检查患者。超声测量ACSA在半卧位和右侧卧位进行内镜手术前。采用胃镜指导吸胃容积(GV)的测量。超声检查评估胃内容物,识别高危胃患者。并评价了ACSA与抽吸GV的关系。结果:782例患者中有736例进行了ACSA评估。右侧侧卧位的ACSA与抽吸的GV呈显著正相关,比半卧位更可靠。分析GV > 100 mL的高危胃,发现右侧卧位ACSA的临界值为7.5 cm2, AUC、敏感性和特异性为0.80 (95% CI, 0.76-0.82;结论:超声测量ACSA可帮助麻醉医师评估全麻及镇静时肺误吸胃内容物的风险。
{"title":"Ultrasonographic Assessment of Gastric Volume in Fasted Patients Undergoing Gastrointestinal Endoscopy Under Sedation.","authors":"Heng Rong,&nbsp;Weixin Dai,&nbsp;Yinying Qin,&nbsp;Zhikeng Meng,&nbsp;Xia Zou,&nbsp;Binbin Wang,&nbsp;Qiufeng Wei,&nbsp;Yubo Xie","doi":"10.2147/TCRM.S424890","DOIUrl":"https://doi.org/10.2147/TCRM.S424890","url":null,"abstract":"<p><strong>Purpose: </strong>In this prospective observational study, an ultrasonographic measurement of antral cross-sectional area (ACSA) was conducted to evaluate the gastric content and volume as well as to identify high-risk stomach in non-pregnant adult surgical patients adhering to preanesthetic fasting guidelines.</p><p><strong>Patients and methods: </strong>Fasted patients undergoing gastrointestinal endoscopy under sedation were included. Ultrasonographic measurements of ACSA were conducted in both semi-recumbent and right lateral decubitus positions before endoscopic procedures. Gastroscopy was employed to guide the measurement of suctioned gastric volume (GV). Ultrasonography was performed to assess gastric contents and identify patients with high-risk stomach. The relationship between ACSA and suctioned GV was also evaluated.</p><p><strong>Results: </strong>ACSA was evaluated in 736 out of 782 patients. A significant positive correlation was discovered between ACSA in the right lateral decubitus position and suctioned GV, which was more reliable than in the semi-recumbent position. To analyze high-risk stomach with a GV > 100 mL, the cutoff value of ACSA in the right lateral decubitus was found to be 7.5 cm<sup>2</sup>, with the AUC, sensitivity and specificity of 0.80 (95% CI, 0.76-0.82; P<0.001), 82.4% and 67.3%, respectively. A novel mathematical model based on ACSA to estimate GV in non-pregnant fasted adults was presented.</p><p><strong>Conclusion: </strong>Ultrasonographic measurement of ACSA can assist anesthesiologists in estimating the risk of pulmonary aspiration of gastric contents during general anesthesia and sedation.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"19 ","pages":"685-698"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/1d/tcrm-19-685.PMC10460589.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10484901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Urinary Incontinence Following Radical Prostatectomy: Challenges and Solutions. 根治性前列腺切除术后尿失禁的处理:挑战和解决方案。
IF 2.8 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S283305
Pietro Castellan, Simone Ferretti, Giulio Litterio, Michele Marchioni, Luigi Schips

Urinary incontinence is a common and debilitating problem in patients undergoing radical prostatectomy. Current methods developed to treat urinary incontinence include conservative treatments, such as lifestyle education, pelvic muscle floor training, pharmacotherapy, and surgical treatments, such as bulking agents use, artificial urinary sphincter implants, retrourethral transobturator slings, and adjustable male sling system. Pelvic floor muscle exercise is the most common management to improve the strength of striated muscles of the pelvic floor to try to recover the sphincter weakness. Antimuscarinic drugs, phosphodiesterase inhibitors, duloxetine, and a-adrenergic drugs have been proposed as medical treatments for urinary incontinence after radical prostatectomy. Development of new surgical techniques, new surgical tools and materials, such as male slings, has provided an improvement of outcomes after UI surgery. Such improvement is still ongoing, and the uptake of new devices might lead to even better outcomes after UI surgery.

尿失禁是在接受根治性前列腺切除术的患者中一个常见和衰弱的问题。目前治疗尿失禁的方法包括保守治疗,如生活方式教育、盆腔肌底训练、药物治疗和手术治疗,如使用膨化剂、人工尿道括约肌植入物、经尿道穿刺吊索和可调节的男性吊索系统。盆底肌肉锻炼是最常见的管理方法,以提高盆底横纹肌的力量,试图恢复括约肌无力。抗毒蕈碱类药物、磷酸二酯酶抑制剂、度洛西汀和a-肾上腺素能药物已被建议作为根治性前列腺切除术后尿失禁的药物治疗。新的手术技术、新的手术工具和材料(如男性吊带)的发展改善了尿失禁手术后的预后。这种改善仍在进行中,新设备的采用可能会在尿失速手术后带来更好的结果。
{"title":"Management of Urinary Incontinence Following Radical Prostatectomy: Challenges and Solutions.","authors":"Pietro Castellan,&nbsp;Simone Ferretti,&nbsp;Giulio Litterio,&nbsp;Michele Marchioni,&nbsp;Luigi Schips","doi":"10.2147/TCRM.S283305","DOIUrl":"https://doi.org/10.2147/TCRM.S283305","url":null,"abstract":"<p><p>Urinary incontinence is a common and debilitating problem in patients undergoing radical prostatectomy. Current methods developed to treat urinary incontinence include conservative treatments, such as lifestyle education, pelvic muscle floor training, pharmacotherapy, and surgical treatments, such as bulking agents use, artificial urinary sphincter implants, retrourethral transobturator slings, and adjustable male sling system. Pelvic floor muscle exercise is the most common management to improve the strength of striated muscles of the pelvic floor to try to recover the sphincter weakness. Antimuscarinic drugs, phosphodiesterase inhibitors, duloxetine, and a-adrenergic drugs have been proposed as medical treatments for urinary incontinence after radical prostatectomy. Development of new surgical techniques, new surgical tools and materials, such as male slings, has provided an improvement of outcomes after UI surgery. Such improvement is still ongoing, and the uptake of new devices might lead to even better outcomes after UI surgery.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"19 ","pages":"43-56"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f0/8f/tcrm-19-43.PMC9851058.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10573299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The Value of Anticoagulation Management Combining Telemedicine and Self-Testing in Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. 远程医疗与自检相结合的抗凝管理在心血管疾病中的价值:一项随机对照试验的meta分析
IF 2.8 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S395578
Yu Huang, Yilian Xie, Lei Huang, Zhen Han

Purpose: No consensus has been established on the safety and effectiveness of out-of-hospital management of Vitamin K antagonists (VKA) therapy combining portable coagulometers and telemedicine. The present meta-analysis investigated the safety and effectiveness of this hybrid anticoagulants management model.

Methods: The PubMed, Embase, Cochrane, and Web of Science databases were searched for papers published before May 1, 2022. To reduce bias, only randomized controlled trials were included. RevMan 5.3 (Cochrane) software was used to evaluate and analyze clinical outcomes, including the effectiveness and safety of patient management approaches, determined by the time in the therapeutic range (TTR) and occurrence of thrombotic and bleeding events.

Results: Eight studies, comprising 3853 patients, were selected. The meta-analysis showed that anticoagulant management combining portable coagulometers and telemedicine significantly improved frequency of testing (mean difference [MD]= 12.95 days; 95% CI, 8.77-17.12; I2= 92%; P< 0.01) and TTR (MD= 9.50%; 95% CI, 3.16-15.85; I2= 87%; P< 0.01). Thromboembolism events were reduced (RR= 0.72; 95% CI, 0.51-1.01; I2= 0%; P= 0.05), but the results were not statistically significant. And no significant differences in major bleeding events, rehospitalization rate, mortality, or overall treatment cost existed between the two groups.

Conclusion: Although the safety of remote cardiovascular disease management is not superior to that of conventional outpatient anticoagulant management, it provides a more stable monitoring of coagulation status.

目的:关于维生素K拮抗剂(VKA)联合便携式凝血仪和远程医疗的院外管理的安全性和有效性尚未达成共识。本荟萃分析调查了这种混合抗凝剂管理模式的安全性和有效性。方法:检索PubMed、Embase、Cochrane和Web of Science数据库,检索2022年5月1日之前发表的论文。为减少偏倚,只纳入随机对照试验。使用RevMan 5.3 (Cochrane)软件评估和分析临床结果,包括患者管理方法的有效性和安全性,由治疗范围内时间(TTR)和血栓和出血事件的发生来确定。结果:入选8项研究,共3853例患者。荟萃分析显示,结合便携式凝血仪和远程医疗的抗凝管理显著提高了检测频率(平均差[MD]= 12.95天;95% ci, 8.77-17.12;I2 = 92%;P< 0.01)和TTR (MD= 9.50%;95% ci, 3.16-15.85;I2 = 87%;P < 0.01)。血栓栓塞事件减少(RR= 0.72;95% ci, 0.51-1.01;I2 = 0%;P= 0.05),但结果无统计学意义。两组在大出血事件、再住院率、死亡率或总治疗费用方面无显著差异。结论:虽然心血管疾病远程管理的安全性并不优于常规门诊抗凝管理,但它提供了更稳定的凝血状态监测。
{"title":"The Value of Anticoagulation Management Combining Telemedicine and Self-Testing in Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials.","authors":"Yu Huang,&nbsp;Yilian Xie,&nbsp;Lei Huang,&nbsp;Zhen Han","doi":"10.2147/TCRM.S395578","DOIUrl":"https://doi.org/10.2147/TCRM.S395578","url":null,"abstract":"<p><strong>Purpose: </strong>No consensus has been established on the safety and effectiveness of out-of-hospital management of Vitamin K antagonists (VKA) therapy combining portable coagulometers and telemedicine. The present meta-analysis investigated the safety and effectiveness of this hybrid anticoagulants management model.</p><p><strong>Methods: </strong>The PubMed, Embase, Cochrane, and Web of Science databases were searched for papers published before May 1, 2022. To reduce bias, only randomized controlled trials were included. RevMan 5.3 (Cochrane) software was used to evaluate and analyze clinical outcomes, including the effectiveness and safety of patient management approaches, determined by the time in the therapeutic range (TTR) and occurrence of thrombotic and bleeding events.</p><p><strong>Results: </strong>Eight studies, comprising 3853 patients, were selected. The meta-analysis showed that anticoagulant management combining portable coagulometers and telemedicine significantly improved frequency of testing (mean difference [MD]= 12.95 days; 95% CI, 8.77-17.12; I<sup>2</sup>= 92%; P< 0.01) and TTR (MD= 9.50%; 95% CI, 3.16-15.85; I<sup>2</sup>= 87%; P< 0.01). Thromboembolism events were reduced (RR= 0.72; 95% CI, 0.51-1.01; I<sup>2</sup>= 0%; P= 0.05), but the results were not statistically significant. And no significant differences in major bleeding events, rehospitalization rate, mortality, or overall treatment cost existed between the two groups.</p><p><strong>Conclusion: </strong>Although the safety of remote cardiovascular disease management is not superior to that of conventional outpatient anticoagulant management, it provides a more stable monitoring of coagulation status.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"19 ","pages":"279-290"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2a/be/tcrm-19-279.PMC10024473.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9156230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma. 免疫检查点抑制剂联合瑞非尼作为二线治疗不可切除肝癌患者的临床疗效和安全性
IF 2.8 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S400079
Jinpeng Li, Yuntao Jia, Changdong Shao, Yuanming Li, Jinlong Song

Purpose: This study aimed to evaluate the safety and efficacy of a combination of programmed death-1 (PD-1) inhibitor and regorafenib as second-line treatment for advanced hepatocellular carcinoma (HCC).

Patients and methods: We retrospectively analyzed the data of 38 patients with unresectable HCC who were treated with PD-1 inhibitor in combination with regorafenib as a second⁃line therapy as well as the data of 32 patients treated with regorafenib only therapy as a control. The clinical data, previous treatment strategies, follow-up imaging results, and adverse events during follow-ups were recorded. The mRECIST Criteria were used to evaluate the treatment outcome of intrahepatic lesions, and the Kaplan-Meier method was used to evaluate survival time.

Results: Up to the last follow-up, the rego-PD-1 group had higher objective response rate (39.5% vs 15.6%, P = 0.028), longer progression-free survival (median 5.9 vs 4.6 months; P = 0.044), and better overall survival (OS) (median 14.5 vs 9.5 months; P = 0.041) than the regorafenib only group. Among the 38 patients in rego-PD-1 group, 1 patient (2.7%) achieved complete response, 14 patients (36.8%) achieved partial response, 14 patients (36.8%) achieved stable disease, and 9 patients (23.7%) achieved progressive disease. Among the 32 patients in regorafenib alone, 5 (15.6%) achieved partial response, 12 (37.5%) achieved stable disease, and 15 (46.9%) achieved progressive disease. Regorafenib alone, Child-Pugh B, and tumors >3 were independent prognostic factors for poor OS. The difference in the incidence of grade 3/4 adverse events between the two groups was not statistically significant (36.8% vs 28.1%; P = 0.439). Grade ≥3 treatment-related adverse events included hypertension and diarrhea.

Conclusion: PD-1 inhibitor combined with regorafenib is a promising regimen in treating patients with unresectable HCC owing to its safety and effectiveness as well as low incidence of serious adverse events with its use.

目的:本研究旨在评估程序性死亡-1 (PD-1)抑制剂联合瑞戈非尼作为晚期肝细胞癌(HCC)二线治疗的安全性和有效性。患者和方法:我们回顾性分析了38例不可切除HCC患者的数据,这些患者接受PD-1抑制剂联合瑞哥非尼作为二线治疗,以及32例仅接受瑞哥非尼作为对照的患者的数据。记录临床资料、既往治疗策略、随访影像结果及随访期间不良事件。采用mRECIST标准评价肝内病变的治疗效果,Kaplan-Meier法评价生存时间。结果:截至最后一次随访,雷戈- pd -1组客观缓解率更高(39.5% vs 15.6%, P = 0.028),无进展生存期更长(中位5.9 vs 4.6个月;P = 0.044)和更好的总生存期(OS)(中位14.5 vs 9.5个月;P = 0.041)。rego-PD-1组38例患者中,完全缓解1例(2.7%),部分缓解14例(36.8%),病情稳定14例(36.8%),病情进展9例(23.7%)。在单独使用瑞非尼的32例患者中,5例(15.6%)达到部分缓解,12例(37.5%)达到疾病稳定,15例(46.9%)达到疾病进展。单独瑞非尼、Child-Pugh B和肿瘤>3是不良OS的独立预后因素。两组患者3/4级不良事件发生率差异无统计学意义(36.8% vs 28.1%;P = 0.439)。≥3级治疗相关不良事件包括高血压和腹泻。结论:PD-1抑制剂联合瑞非尼治疗不可切除HCC安全有效,严重不良事件发生率低,是一种有前景的治疗方案。
{"title":"Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma.","authors":"Jinpeng Li,&nbsp;Yuntao Jia,&nbsp;Changdong Shao,&nbsp;Yuanming Li,&nbsp;Jinlong Song","doi":"10.2147/TCRM.S400079","DOIUrl":"https://doi.org/10.2147/TCRM.S400079","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the safety and efficacy of a combination of programmed death-1 (PD-1) inhibitor and regorafenib as second-line treatment for advanced hepatocellular carcinoma (HCC).</p><p><strong>Patients and methods: </strong>We retrospectively analyzed the data of 38 patients with unresectable HCC who were treated with PD-1 inhibitor in combination with regorafenib as a second⁃line therapy as well as the data of 32 patients treated with regorafenib only therapy as a control. The clinical data, previous treatment strategies, follow-up imaging results, and adverse events during follow-ups were recorded. The mRECIST Criteria were used to evaluate the treatment outcome of intrahepatic lesions, and the Kaplan-Meier method was used to evaluate survival time.</p><p><strong>Results: </strong>Up to the last follow-up, the rego-PD-1 group had higher objective response rate (39.5% vs 15.6%, P = 0.028), longer progression-free survival (median 5.9 vs 4.6 months; P = 0.044), and better overall survival (OS) (median 14.5 vs 9.5 months; P = 0.041) than the regorafenib only group. Among the 38 patients in rego-PD-1 group, 1 patient (2.7%) achieved complete response, 14 patients (36.8%) achieved partial response, 14 patients (36.8%) achieved stable disease, and 9 patients (23.7%) achieved progressive disease. Among the 32 patients in regorafenib alone, 5 (15.6%) achieved partial response, 12 (37.5%) achieved stable disease, and 15 (46.9%) achieved progressive disease. Regorafenib alone, Child-Pugh B, and tumors >3 were independent prognostic factors for poor OS. The difference in the incidence of grade 3/4 adverse events between the two groups was not statistically significant (36.8% vs 28.1%; P = 0.439). Grade ≥3 treatment-related adverse events included hypertension and diarrhea.</p><p><strong>Conclusion: </strong>PD-1 inhibitor combined with regorafenib is a promising regimen in treating patients with unresectable HCC owing to its safety and effectiveness as well as low incidence of serious adverse events with its use.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"19 ","pages":"329-339"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3e/ce/tcrm-19-329.PMC10083010.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9290092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug-Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA). 多药治疗和衰老对接受泛型直接作用抗病毒药物(pDAA)治疗的HCV患者多重药物-药物相互作用(ddi)风险影响的意大利真实世界分析
IF 2.8 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S394467
Stefano Fagiuoli, Pierluigi Toniutto, Nicola Coppola, Domenica Daniela Ancona, Margherita Andretta, Fausto Bartolini, Fulvio Ferrante, Alessandro Lupi, Stefano Palcic, Francesca Vittoria Rizzi, Davide Re, Gema Alvarez Nieto, Candido Hernandez, Francesca Frigerio, Valentina Perrone, Luca Degli Esposti, Alessandra Mangia

Purpose: The study aims at investigating the impact of polymedication and aging in the prevalence of multiple drug-drug interactions (DDIs) on HCV patients treated with sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB).

Patients and methods: This is a retrospective analysis based on administrative data covering around 6.9 million individuals. Patients treated with SOF/VEL or GLE/PIB over November 2017-March 2020 were included. Index date corresponded to SOF/VEL or GLE/PIB first prescription during such period; patients were followed up for treatment duration. Analyses were then focused on patients with ≥2 comedications at risk of multiple DDIs. The severity and the effect of multiple DDI were identified using the Liverpool University tool.

Results: A total of 2057 patients with SOF/VEL and 2128 with GLE/PIB were selected. Mean age of SOF/VEL patients was 58.5 years, higher than GLE/PIB ones (52.5 years) (p < 0.001), and patients >50 years were more present in SOF/VEL vs GLE/PIB cohorts: 72% vs 58%, (p < 0.001). Most prescribed co-medications were cardiovascular, alimentary and nervous system drugs. Proportion of patients with ≥2 comedications was higher in SOF/VEL compared to GLE/PIB cohort (56.5% vs 32.3%, p < 0.001). Those at high-risk of multiple DDIs accounted for 11.6% (N = 135) of SOF/VEL and 19.6% (N = 135) of GLE/PIB (p < 0.001) patients with ≥2 comedications. Among them, the potential effect of DDI was a decrease of DAA serum levels (11% of SOF/VEL and GLE/PIB patients) and an increased concentration of comedication serum levels (14% of SOF/VEL and 42% of GLE/PIB patients).

Conclusion: This real-world analysis provided a thorough characterization on the burden of polymedication regimens in HCV patients treated with SOF/VEL or GLE/PIB that expose such patients to an increased risk of DDIs. In our sample population, SOF/VEL regimen was more frequently detected on elderly patients and on those with ≥2 comedications at risk of multi-DDI, ie, among patients characterized by higher rates of comorbidities and polypharmacy.

目的:本研究旨在探讨多种药物和年龄对使用索非布韦/维帕他韦(SOF/VEL)或glecaprevir/pibrentasvir (GLE/PIB)治疗的HCV患者多重药物相互作用(ddi)发生率的影响。患者和方法:这是一项基于约690万人的行政数据的回顾性分析。纳入2017年11月至2020年3月期间接受SOF/VEL或GLE/PIB治疗的患者。与此期间的SOF/VEL或GLE/PIB首开处方对应的索引日期;随访患者治疗时间。然后将分析重点放在具有多重ddi风险的≥2种药物的患者。使用利物浦大学的工具确定多重DDI的严重程度和影响。结果:共入选SOF/VEL患者2057例,GLE/PIB患者2128例。SOF/VEL患者的平均年龄为58.5岁,高于GLE/PIB患者的平均年龄(52.5岁)(p < 0.001),并且>50岁的患者在SOF/VEL和GLE/PIB队列中更多:72%比58%,(p < 0.001)。大多数联合用药是心血管、消化和神经系统药物。使用≥2种药物的患者比例在SOF/VEL组高于GLE/PIB组(56.5% vs 32.3%, p < 0.001)。≥2种药物治疗的SOF/VEL患者中有11.6% (N = 135)存在多重ddi高危,GLE/PIB患者中有19.6% (N = 135)存在多重ddi高危(p < 0.001)。其中,DDI的潜在影响是降低血清DAA水平(占SOF/VEL和GLE/PIB患者的11%),增加血清药物浓度(占SOF/VEL的14%和GLE/PIB的42%)。结论:这一真实世界的分析提供了一个全面的特征,即在接受SOF/VEL或GLE/PIB治疗的HCV患者中,多重药物治疗方案的负担使这些患者的ddi风险增加。在我们的样本人群中,SOF/VEL方案在老年患者和使用≥2种药物有多重ddi风险的患者中更常见,即在合并症和多种药物发生率较高的患者中。
{"title":"Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug-Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA).","authors":"Stefano Fagiuoli,&nbsp;Pierluigi Toniutto,&nbsp;Nicola Coppola,&nbsp;Domenica Daniela Ancona,&nbsp;Margherita Andretta,&nbsp;Fausto Bartolini,&nbsp;Fulvio Ferrante,&nbsp;Alessandro Lupi,&nbsp;Stefano Palcic,&nbsp;Francesca Vittoria Rizzi,&nbsp;Davide Re,&nbsp;Gema Alvarez Nieto,&nbsp;Candido Hernandez,&nbsp;Francesca Frigerio,&nbsp;Valentina Perrone,&nbsp;Luca Degli Esposti,&nbsp;Alessandra Mangia","doi":"10.2147/TCRM.S394467","DOIUrl":"https://doi.org/10.2147/TCRM.S394467","url":null,"abstract":"<p><strong>Purpose: </strong>The study aims at investigating the impact of polymedication and aging in the prevalence of multiple drug-drug interactions (DDIs) on HCV patients treated with sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB).</p><p><strong>Patients and methods: </strong>This is a retrospective analysis based on administrative data covering around 6.9 million individuals. Patients treated with SOF/VEL or GLE/PIB over November 2017-March 2020 were included. Index date corresponded to SOF/VEL or GLE/PIB first prescription during such period; patients were followed up for treatment duration. Analyses were then focused on patients with ≥2 comedications at risk of multiple DDIs. The severity and the effect of multiple DDI were identified using the Liverpool University tool.</p><p><strong>Results: </strong>A total of 2057 patients with SOF/VEL and 2128 with GLE/PIB were selected. Mean age of SOF/VEL patients was 58.5 years, higher than GLE/PIB ones (52.5 years) (p < 0.001), and patients >50 years were more present in SOF/VEL vs GLE/PIB cohorts: 72% vs 58%, (p < 0.001). Most prescribed co-medications were cardiovascular, alimentary and nervous system drugs. Proportion of patients with ≥2 comedications was higher in SOF/VEL compared to GLE/PIB cohort (56.5% vs 32.3%, p < 0.001). Those at high-risk of multiple DDIs accounted for 11.6% (N = 135) of SOF/VEL and 19.6% (N = 135) of GLE/PIB (p < 0.001) patients with ≥2 comedications. Among them, the potential effect of DDI was a decrease of DAA serum levels (11% of SOF/VEL and GLE/PIB patients) and an increased concentration of comedication serum levels (14% of SOF/VEL and 42% of GLE/PIB patients).</p><p><strong>Conclusion: </strong>This real-world analysis provided a thorough characterization on the burden of polymedication regimens in HCV patients treated with SOF/VEL or GLE/PIB that expose such patients to an increased risk of DDIs. In our sample population, SOF/VEL regimen was more frequently detected on elderly patients and on those with ≥2 comedications at risk of multi-DDI, ie, among patients characterized by higher rates of comorbidities and polypharmacy.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"19 ","pages":"57-65"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a2/87/tcrm-19-57.PMC9868280.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9177547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Adherence to Continuous Positive Airway Pressure Therapy in Pediatric Patients with Obstructive Sleep Apnea: A Meta-Analysis. 阻塞性睡眠呼吸暂停患儿坚持持续气道正压治疗:一项荟萃分析。
IF 2.8 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S358737
Bundit Sawunyavisuth, Chetta Ngamjarus, Kittisak Sawanyawisuth

Introduction: Obstructive sleep apnea (OSA) is a public health problem that affects children. Although continuous positive airway pressure (CPAP) therapy is effective, the CPAP adherence rate in children is varied. This study aimed to evaluate the CPAP adherence rate and factors associated with CPAP adherence in children with OSA using a systematic review.

Methods: The inclusion criteria were observational studies conducted in children with OSA and assessed adherence of CPAP using objective evaluation. The literature search was performed in four databases. Meta-analysis using fixed-effect model was conducted to combine results among included studies.

Results: In all, 34 studies that evaluated adherence rate and predictors of CPAP adherence in children with OSA were included, representing 21,737 patients with an average adherence rate of 46.56%. There were 11 calculations of factors predictive of CPAP adherence: age, sex, ethnicity, body mass index, obesity, income, sleep efficiency, the apnea-hypopnea index (AHI), severity of OSA, residual AHI, and lowest oxygen saturation level. Three different factors were linked to children with adherence and non-adherence to CPAP: age, body mass index, and AHI.

Conclusion: The CPAP adherence rate in children with OSA was 46.56%. Young age, low body mass index, and high AHI were associated with acceptable CPAP adherence in children with OSA.

梗阻性睡眠呼吸暂停(OSA)是影响儿童的公共卫生问题。虽然持续气道正压(CPAP)治疗是有效的,但儿童的CPAP依从率各不相同。本研究旨在通过系统回顾评估阻塞性睡眠呼吸暂停(OSA)患儿的CPAP依从率和与CPAP依从性相关的因素。方法:纳入标准为对OSA患儿进行观察性研究,采用客观评价法评估CPAP的依从性。在四个数据库中进行文献检索。采用固定效应模型进行meta分析,将纳入研究的结果合并。结果:总共纳入34项评估OSA患儿CPAP依从率和预测因素的研究,共21737例患者,平均依从率为46.56%。有11个预测CPAP依从性的因素计算:年龄、性别、种族、体重指数、肥胖、收入、睡眠效率、呼吸暂停低通气指数(AHI)、OSA严重程度、残留AHI和最低血氧饱和度。三个不同的因素与坚持和不坚持CPAP的儿童有关:年龄、体重指数和AHI。结论:OSA患儿CPAP依从率为46.56%。年龄小、低体重指数和高AHI与OSA患儿可接受的CPAP依从性相关。
{"title":"Adherence to Continuous Positive Airway Pressure Therapy in Pediatric Patients with Obstructive Sleep Apnea: A Meta-Analysis.","authors":"Bundit Sawunyavisuth,&nbsp;Chetta Ngamjarus,&nbsp;Kittisak Sawanyawisuth","doi":"10.2147/TCRM.S358737","DOIUrl":"https://doi.org/10.2147/TCRM.S358737","url":null,"abstract":"<p><strong>Introduction: </strong>Obstructive sleep apnea (OSA) is a public health problem that affects children. Although continuous positive airway pressure (CPAP) therapy is effective, the CPAP adherence rate in children is varied. This study aimed to evaluate the CPAP adherence rate and factors associated with CPAP adherence in children with OSA using a systematic review.</p><p><strong>Methods: </strong>The inclusion criteria were observational studies conducted in children with OSA and assessed adherence of CPAP using objective evaluation. The literature search was performed in four databases. Meta-analysis using fixed-effect model was conducted to combine results among included studies.</p><p><strong>Results: </strong>In all, 34 studies that evaluated adherence rate and predictors of CPAP adherence in children with OSA were included, representing 21,737 patients with an average adherence rate of 46.56%. There were 11 calculations of factors predictive of CPAP adherence: age, sex, ethnicity, body mass index, obesity, income, sleep efficiency, the apnea-hypopnea index (AHI), severity of OSA, residual AHI, and lowest oxygen saturation level. Three different factors were linked to children with adherence and non-adherence to CPAP: age, body mass index, and AHI.</p><p><strong>Conclusion: </strong>The CPAP adherence rate in children with OSA was 46.56%. Young age, low body mass index, and high AHI were associated with acceptable CPAP adherence in children with OSA.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"19 ","pages":"143-162"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/2d/tcrm-19-143.PMC9904217.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10679730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Identifying the Risk Factors for Postoperative Sore Throat After Endotracheal Intubation for Oral and Maxillofacial Surgery. 口腔颌面外科气管插管术后咽喉痛的危险因素分析。
IF 2.8 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S396687
Zhou-Peng Zheng, Su-Lin Tang, Shao-Lan Fu, Qian Wang, Li-Wei Jin, Yan-Li Zhang, Rong-Rong Huang

Objective: To identify risk factors for postoperative sore throat (POST) after general anesthesia in oral and maxillOfacial surgery.

Material and methods: This study is a retrospective cohort design study. We enrolled patients with oral and maxillofacial surgery who underwent endotracheal intubation under general anesthesia in the Stomatology Hospital, Zhejiang University School Of Medicine between April 2020 and April 2021. They were divided into the POST group and the without POST group. The distribution Of various characteristics in the two groups was firstly analyzed. Then, logistic regression analysis was performed to explore the independent predictors for POST occurrence. Following this, logistic regression and random forest models were constructed and their performance was evaluated to predict POST occurrence.

Results: A total of 891 participants were enrolled in the study. Female gender and cough during extubation were significantly associated with increased POST occurrence in multivariate analysis (all P <0.05). Stratified logistic regression analysis results showed that the female gender was an independent predictor for POST occurrence in the 4≤age≤14 and 1460 group after adjusting American Society of Anesthesiologists status and throat and lung disease (all P <0.05). The logistic regression model had a similar effect to the random forest model in predicting POST occurrence. Interestingly, the female gender had a higher important weight compared to the cough during extubation.

Conclusion: This research reveals female gender and cough during extubation as potential risk factors for POST occurrence, which may provide guidance for the effective prevention of POST in oral and maxillofacial surgery.

目的:探讨口腔颌面外科手术全身麻醉后咽喉痛的危险因素。材料与方法:本研究为回顾性队列设计研究。我们招募了2020年4月至2021年4月在浙江大学医学院口腔医院接受全身麻醉气管插管的口腔颌面外科患者。他们被分为POST组和未POST组。首先分析了两组各特征的分布。然后进行logistic回归分析,探讨POST发生的独立预测因素。随后,构建了逻辑回归和随机森林模型,并对其预测POST发生的性能进行了评估。结果:共有891名参与者被纳入研究。多因素分析显示,女性性别和拔管时咳嗽与POST发生增加有显著相关性(调整美国麻醉医师协会身份和咽喉及肺部疾病后均P 60组)。结论:本研究揭示了女性性别和拔管时咳嗽是POST发生的潜在危险因素,可为口腔颌面外科手术中有效预防POST提供指导。
{"title":"Identifying the Risk Factors for Postoperative Sore Throat After Endotracheal Intubation for Oral and Maxillofacial Surgery.","authors":"Zhou-Peng Zheng,&nbsp;Su-Lin Tang,&nbsp;Shao-Lan Fu,&nbsp;Qian Wang,&nbsp;Li-Wei Jin,&nbsp;Yan-Li Zhang,&nbsp;Rong-Rong Huang","doi":"10.2147/TCRM.S396687","DOIUrl":"https://doi.org/10.2147/TCRM.S396687","url":null,"abstract":"<p><strong>Objective: </strong>To identify risk factors for postoperative sore throat (POST) after general anesthesia in oral and maxillOfacial surgery.</p><p><strong>Material and methods: </strong>This study is a retrospective cohort design study. We enrolled patients with oral and maxillofacial surgery who underwent endotracheal intubation under general anesthesia in the Stomatology Hospital, Zhejiang University School Of Medicine between April 2020 and April 2021. They were divided into the POST group and the without POST group. The distribution Of various characteristics in the two groups was firstly analyzed. Then, logistic regression analysis was performed to explore the independent predictors for POST occurrence. Following this, logistic regression and random forest models were constructed and their performance was evaluated to predict POST occurrence.</p><p><strong>Results: </strong>A total of 891 participants were enrolled in the study. Female gender and cough during extubation were significantly associated with increased POST occurrence in multivariate analysis (all P <0.05). Stratified logistic regression analysis results showed that the female gender was an independent predictor for POST occurrence in the 4≤age≤14 and 14<age≤60 groups after adjusting all the covariates, while cough during extubation independently predicted POST in the age>60 group after adjusting American Society of Anesthesiologists status and throat and lung disease (all P <0.05). The logistic regression model had a similar effect to the random forest model in predicting POST occurrence. Interestingly, the female gender had a higher important weight compared to the cough during extubation.</p><p><strong>Conclusion: </strong>This research reveals female gender and cough during extubation as potential risk factors for POST occurrence, which may provide guidance for the effective prevention of POST in oral and maxillofacial surgery.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"19 ","pages":"163-170"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/a7/tcrm-19-163.PMC9926977.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10738714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in Anxiety and Depression After THA in Patients with Ankylosing Spondylitis and the Affecting Factors. 强直性脊柱炎患者THA术后焦虑、抑郁的变化及影响因素
IF 2.8 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S415564
Hang Qian, Xu Wang, Pengbo Wang, Guangyang Zhang, Jun Liu, Xiaoqian Dang, Jianbin Guo, Ruiyu Liu

Objective: Hip ankylosis is a prevalent condition in patients with Ankylosing spondylitis (AS) that can significantly impact their psychological well-being. This study aimed to investigate the impact of Total Hip Arthroplasty (THA) on anxiety and depression among AS patients.

Methods: 62 AS patients undergoing primary THA were recruited and separated into two groups based on preoperative hip motion. The 40 patients with hip mobility of 0° were assigned to group A, and others were assigned to group NA. Self-rating Anxiety Scale (SAS), Self-rating Depression scale (SDS), Harris hip scores (HHS) and 36-Item Short Form Survey (SF-36) were obtained one week before and there, six and twelve months after THA.

Results: The study found that AS patients in group A had significantly higher levels of anxiety and depression (SAS score = 75.05±2.79, SDS index score = 0.74±0.02) compared to group B (SAS score = 54.58±3.35, SDS index score= 0.64±0.03, P=0.01). However, both groups showed significant improvements in anxiety and depression scores from there to twelve months after THA (P<0.001). Correlation analyses revealed that the improvement in group NA was associated with hip pain relief (p<0.001), while the improvement in group A was related to joint function, disease duration, age at THA and spine imaging lesions (p<0.001).

Conclusion: Some degree of anxiety and depression was present in both groups of AS patients. Levels of depression and anxiety were higher in patients with combined hip ankylosis. And their improvement was associated with improved hip function and quality of life after THA. Hip pain relief played a significant role in patients without hip joint ankylosis. The impact of the degree of lesion on spinal imaging on psychological status needs to be considered in both groups.

目的:髋关节强直性脊柱炎是强直性脊柱炎(AS)患者的一种常见疾病,可以显著影响他们的心理健康。本研究旨在探讨全髋关节置换术(THA)对AS患者焦虑和抑郁的影响。方法:选取62例行原发性全髋关节置换术的AS患者,根据术前髋关节运动情况分为两组。40例髋关节活动度为0°的患者分为A组,其余患者分为NA组。在THA前1周、THA后6个月、THA后12个月分别进行焦虑自评量表(SAS)、抑郁自评量表(SDS)、Harris髋关节评分(HHS)和36项简短问卷调查(SF-36)。结果:研究发现A组AS患者焦虑、抑郁水平(SAS评分= 75.05±2.79,SDS指数评分= 0.74±0.02)显著高于B组(SAS评分= 54.58±3.35,SDS指数评分= 0.64±0.03,P=0.01)。然而,两组患者在THA后12个月的焦虑和抑郁评分均有显著改善(结论:两组AS患者均存在一定程度的焦虑和抑郁。合并髋关节强直患者的抑郁和焦虑水平较高。他们的改善与髋关节功能的改善和THA后的生活质量有关。在无髋关节强直的患者中,髋关节疼痛缓解有显著作用。两组均需考虑脊柱影像学病变程度对心理状态的影响。
{"title":"Changes in Anxiety and Depression After THA in Patients with Ankylosing Spondylitis and the Affecting Factors.","authors":"Hang Qian,&nbsp;Xu Wang,&nbsp;Pengbo Wang,&nbsp;Guangyang Zhang,&nbsp;Jun Liu,&nbsp;Xiaoqian Dang,&nbsp;Jianbin Guo,&nbsp;Ruiyu Liu","doi":"10.2147/TCRM.S415564","DOIUrl":"https://doi.org/10.2147/TCRM.S415564","url":null,"abstract":"<p><strong>Objective: </strong>Hip ankylosis is a prevalent condition in patients with Ankylosing spondylitis (AS) that can significantly impact their psychological well-being. This study aimed to investigate the impact of Total Hip Arthroplasty (THA) on anxiety and depression among AS patients.</p><p><strong>Methods: </strong>62 AS patients undergoing primary THA were recruited and separated into two groups based on preoperative hip motion. The 40 patients with hip mobility of 0° were assigned to group A, and others were assigned to group NA. Self-rating Anxiety Scale (SAS), Self-rating Depression scale (SDS), Harris hip scores (HHS) and 36-Item Short Form Survey (SF-36) were obtained one week before and there, six and twelve months after THA.</p><p><strong>Results: </strong>The study found that AS patients in group A had significantly higher levels of anxiety and depression (SAS score = 75.05±2.79, SDS index score = 0.74±0.02) compared to group B (SAS score = 54.58±3.35, SDS index score= 0.64±0.03, P=0.01). However, both groups showed significant improvements in anxiety and depression scores from there to twelve months after THA (P<0.001). Correlation analyses revealed that the improvement in group NA was associated with hip pain relief (p<0.001), while the improvement in group A was related to joint function, disease duration, age at THA and spine imaging lesions (p<0.001).</p><p><strong>Conclusion: </strong>Some degree of anxiety and depression was present in both groups of AS patients. Levels of depression and anxiety were higher in patients with combined hip ankylosis. And their improvement was associated with improved hip function and quality of life after THA. Hip pain relief played a significant role in patients without hip joint ankylosis. The impact of the degree of lesion on spinal imaging on psychological status needs to be considered in both groups.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"19 ","pages":"675-684"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bb/49/tcrm-19-675.PMC10439721.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10048630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients. 评价他克莫司治疗膜性肾病的疗效和安全性:182例患者的回顾性研究结果。
IF 2.8 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Pub Date : 2023-01-01 DOI: 10.2147/TCRM.S399218
Shuang Liang, Yan-Jun Liang, Zhao Li, Yong Wang, Xin-Ru Guo, Chao-Yang Zhang, Chun Zhang, Jie Wu, Xiao-Long Wang, Yi-Sha Li, Guang-Yan Cai, Xiang-Mei Chen

Purpose: Tacrolimus is recommended by KDIGO Clinical Practice Guidelines as an initial therapy for the treatment of membranous nephropathy (MN). However, little is known about the factors that influence response and recurrence of the disease after tacrolimus therapy, and there are limited data regarding the duration of tacrolimus treatment. Here, we present a real-world retrospective cohort study of 182 MN patients treated with tacrolimus, aiming to assess the efficacy and safety of tacrolimus in the treatment of MN.

Patients and methods: The clinical data of 182 patients with MN treated with tacrolimus and followed up for at least one year were analyzed retrospectively for the efficacy and safety of tacrolimus.

Results: The mean follow-up period was 27.3 (19.3-41.6) months. A total of 154 patients (84.6%) achieved complete or partial remission, and 28 patients (15.4%) did not. Multivariate Cox regression analysis showed that male and higher baseline BMI were independently associated with lower, while higher serum albumin was associated with higher probability of remission. Among the responders, 56 patients (36.4%) relapsed. After adjustments for age and sex, Cox regression analysis revealed that the longer period of full-dose tacrolimus was administered, the lower the incidence of relapse. However, high levels of serum creatinine and proteinuria at the onset of tacrolimus discontinuation were risk factors for relapse. During the treatment of tacrolimus, a decline in renal function (≥50% increase in serum creatinine after the onset of tacrolimus treatment) was the most common adverse reaction, observed in 20 (11.0%) patients, followed by elevated blood glucose and infection, but the latter two occurred mostly during treatment with tacrolimus plus corticosteroids.

Conclusion: Tacrolimus is effective in the treatment of MN, but the relapse rate is high. Clinical studies with larger sample sizes are needed to further explore the use of tacrolimus in the treatment of membranous nephropathy.

目的:KDIGO临床实践指南推荐他克莫司作为膜性肾病(MN)的初始治疗。然而,对影响他克莫司治疗后反应和疾病复发的因素知之甚少,关于他克莫司治疗持续时间的数据有限。在此,我们对182例接受他克莫司治疗的MN患者进行了一项真实世界的回顾性队列研究,旨在评估他克莫司治疗MN的有效性和安全性。患者和方法:回顾性分析182例接受他克莫司治疗并随访1年以上的MN患者的临床资料,探讨他克莫司的疗效和安全性。结果:平均随访时间27.3(19.3 ~ 41.6)个月。154例患者(84.6%)达到完全或部分缓解,28例患者(15.4%)没有。多因素Cox回归分析显示,男性和较高的基线BMI与较低的血清白蛋白独立相关,而较高的血清白蛋白与较高的缓解概率相关。在应答者中,56例(36.4%)复发。在调整年龄和性别后,Cox回归分析显示,全剂量他克莫司给药时间越长,复发率越低。然而,他克莫司停药时血清肌酐和蛋白尿水平高是复发的危险因素。在他克莫司治疗期间,肾功能下降(他克莫司治疗开始后血清肌酐升高≥50%)是最常见的不良反应,20例(11.0%)患者观察到,其次是血糖升高和感染,但后两者主要发生在他克莫司联合皮质类固醇治疗期间。结论:他克莫司治疗MN有效,但复发率高。需要更大样本量的临床研究来进一步探讨他克莫司在膜性肾病治疗中的应用。
{"title":"Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients.","authors":"Shuang Liang,&nbsp;Yan-Jun Liang,&nbsp;Zhao Li,&nbsp;Yong Wang,&nbsp;Xin-Ru Guo,&nbsp;Chao-Yang Zhang,&nbsp;Chun Zhang,&nbsp;Jie Wu,&nbsp;Xiao-Long Wang,&nbsp;Yi-Sha Li,&nbsp;Guang-Yan Cai,&nbsp;Xiang-Mei Chen","doi":"10.2147/TCRM.S399218","DOIUrl":"https://doi.org/10.2147/TCRM.S399218","url":null,"abstract":"<p><strong>Purpose: </strong>Tacrolimus is recommended by KDIGO Clinical Practice Guidelines as an initial therapy for the treatment of membranous nephropathy (MN). However, little is known about the factors that influence response and recurrence of the disease after tacrolimus therapy, and there are limited data regarding the duration of tacrolimus treatment. Here, we present a real-world retrospective cohort study of 182 MN patients treated with tacrolimus, aiming to assess the efficacy and safety of tacrolimus in the treatment of MN.</p><p><strong>Patients and methods: </strong>The clinical data of 182 patients with MN treated with tacrolimus and followed up for at least one year were analyzed retrospectively for the efficacy and safety of tacrolimus.</p><p><strong>Results: </strong>The mean follow-up period was 27.3 (19.3-41.6) months. A total of 154 patients (84.6%) achieved complete or partial remission, and 28 patients (15.4%) did not. Multivariate Cox regression analysis showed that male and higher baseline BMI were independently associated with lower, while higher serum albumin was associated with higher probability of remission. Among the responders, 56 patients (36.4%) relapsed. After adjustments for age and sex, Cox regression analysis revealed that the longer period of full-dose tacrolimus was administered, the lower the incidence of relapse. However, high levels of serum creatinine and proteinuria at the onset of tacrolimus discontinuation were risk factors for relapse. During the treatment of tacrolimus, a decline in renal function (≥50% increase in serum creatinine after the onset of tacrolimus treatment) was the most common adverse reaction, observed in 20 (11.0%) patients, followed by elevated blood glucose and infection, but the latter two occurred mostly during treatment with tacrolimus plus corticosteroids.</p><p><strong>Conclusion: </strong>Tacrolimus is effective in the treatment of MN, but the relapse rate is high. Clinical studies with larger sample sizes are needed to further explore the use of tacrolimus in the treatment of membranous nephropathy.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"19 ","pages":"351-360"},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/af/tcrm-19-351.PMC10106312.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9738489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Therapeutics and Clinical Risk Management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1